31 results match your criteria: "Research Institute for Development IRD[Affiliation]"
J Venom Anim Toxins Incl Trop Dis
June 2015
UMR 216, Mother and Child Facing Tropical Diseases, Research Institute for Development (IRD), 08 BP 841 Cotonou, Benin ; School of Pharmacy, Paris Descartes University, Sorbonne, Paris Cité, France.
J Venom Anim Toxins Incl Trop Dis
February 2015
Institute of Biotechnology, National Autonomous University of Mexico (UNAM), Cuernavaca, Morelos Mexico.
Background: Better treatments are urgently needed for the management of Ebola virus epidemics in Equatorial Africa.
Methods: We conducted a systematic review of the literature on the use of passive immunotherapy for the treatment or prevention of Ebola virus disease. We placed findings from this review into the context of passive immunotherapy currently used for venom-induced disease, and recent improvements in manufacturing of polyvalent antivenom products.
PLoS Negl Trop Dis
December 2014
Paris-Est University, Anses, Laboratory for Animal Health, Epidemiology Unit, Maisons-Alfort, France.
Rift Valley fever (RVF) is a vector-borne zoonotic disease that causes high morbidity and mortality in ruminants. In 2008-2009, a RVF outbreak affected the whole Madagascar island, including the Anjozorobe district located in Madagascar highlands. An entomological survey showed the absence of Aedes among the potential RVF virus (RVFV) vector species identified in this area, and an overall low abundance of mosquitoes due to unfavorable climatic conditions during winter.
View Article and Find Full Text PDFTrop Med Int Health
October 2007
UMR 145 HIV/AIDS and Associated Diseases, Research Institute for Development (IRD)/University of Montpellier, 911 avenue Agropolis, 34394 Montpellier Cedex 1, France.
Objectives: To assess long-term adherence of the first HIV-1 patients receiving highly active antiretroviral therapy (HAART) in Senegal, and to identify the main determinants of adherence.
Methods: The first 180 patients enrolled in the Senegalese HAART initiative between August 1998 and April 2001 followed up for at least 30 days were eligible. Adherence was assessed monthly at each drug dispensation between November 1999 and November 2006 by a pharmacist using a pill count completed by a questionnaire.
AIDS
May 2006
UMR 145 HIV/AIDS and Associated Diseases, Research Institute for Development (IRD)/University of Montpellier, 911 avenue Agropolis, 34394 Montpellier Cedex 1, France.
Objectives: To evaluate survival and investigate causes of death among HIV-1 infected adults receiving HAART in Senegal.
Design: An observational prospective cohort.
Methods: Mortality was assessed in the first patients enrolled between August 1998 and April 2002 in the Senegalese antiretroviral drug access initiative.
Adv Exp Med Biol
October 2001
Research Institute for Development (IRD), Montpellier, France.